Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theravance - THRX -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (39)	8/28/2006 10:22:51 AM
From: Biomaven	Read Replies (2) \| Respond to of 74

hitting on superiority while missing on non-inferiority is rare, but it can happen Could you give an example? See the abstract on this issue I posted on the valuation thread. Further, your two-bites analysis would presumably imply a .025 level for the non-inferiority trial as well, but there is no mention of that. I do grant that .025 is suggestive of a two-bite analysis - I just don't understand why. These two presentations are interesting: findarticles.com amstat.org Peter